Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis

Summary

The proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon.

Timeline

Start

2026-02-10

Primary completion

2028-10

Completion

2029-03

Drugs

Indications